Skip to content

Study on Habb-e-Mujarrab for Relief and Safety of Migraine

Clinical Study to evaluate the efficacy and safety of Habb e Mujarrab in the management of Shaqiqa (Migraine) - Migraine

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090450
Enrollment
38
Registered
2025-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G430- Migraine without aura

Interventions

Intervention1: Habb e Mujarrab: Elwa (Alove barbidensis) 1 gm Chirata (Swertia chirata) 1 gm Jaiphal (Myristrica fragrance) 2 gm Zeera safaid (Cuminum cyminum) 3 gm Ajmod (Apium graveolens) 3 gm N

Sponsors

State Takmeel ut tib college and hospital near ramabai railly sthal lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinically diagnosed based on ICHD-3 diagnostic criteria for Migrainee A At least five Attack fulfilling criteria B-D B Headache attack lasting 4-72hr C Headache has at least two of the following four characteristic: Unilateral location pulsating quality, moderate or severe pain intensity, aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs) D. During headache, at least one of the following: Nausea and vomiting Photophobia and phonophobia E. Exclusion of secondary cause of Headach 3. Patient willing to sign written informed consent

Exclusion criteria

Exclusion criteria: Participant below 18 years and above 60 years of age. 2 Non-migrationeous headache; cluster headache; chronic paroxysmal or nonparoxysmal hemicranias 3 Patient with neuropsychiatric illness. 4 Pregnancy and lactating women. 5 Patients with systemic illness and metabolic diseases 6. Patients unsure about attending treatment schedule regularly. 7. Patients with the history of trauma and accidents. 8. Familial hemiplegic migraine

Design outcomes

Primary

MeasureTime frame
Visual Analogue scale (VAS) Migraine disability assessment (MIDAS) The number of rescue medication (e.g. simple analgesic, combination analgesics, ergotamine, triptans) taken within three months before and after the commencement of the treatmentTimepoint: 15th, 30th, 45th, 60th, 75th 90th day

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Gulnaz Fatima

State Takmeel ut tib college and hospital

aq.ayaz5775@gmail.com9415757169

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026